Enhancing in situ cancer vaccines using delivery technologies.

Autor: Gong N; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.; School of Basic Medical Sciences, Division of Life Sciences and Medicine, Center for BioAnalytical Chemistry, Hefei National Research Center for Physical Science at the Microscale, University of Science and Technology of China, Hefei, China., Alameh MG; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Penn institute for RNA innovation, University of Pennsylvania, Philadelphia, PA, USA.; Department of Bioengineering, George Mason University, Fairfax, VA, USA., El-Mayta R; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Xue L; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA., Weissman D; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dreww@upenn.edu.; Penn institute for RNA innovation, University of Pennsylvania, Philadelphia, PA, USA. dreww@upenn.edu., Mitchell MJ; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.; Penn institute for RNA innovation, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.; Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.
Jazyk: angličtina
Zdroj: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2024 Aug; Vol. 23 (8), pp. 607-625. Date of Electronic Publication: 2024 Jul 01.
DOI: 10.1038/s41573-024-00974-9
Abstrakt: In situ cancer vaccination refers to any approach that exploits tumour antigens available at a tumour site to induce tumour-specific adaptive immune responses. These approaches hold great promise for the treatment of many solid tumours, with numerous candidate drugs under preclinical or clinical evaluation and several products already approved. However, there are challenges in the development of effective in situ cancer vaccines. For example, inadequate release of tumour antigens from tumour cells limits antigen uptake by immune cells; insufficient antigen processing by antigen-presenting cells restricts the generation of antigen-specific T cell responses; and the suppressive immune microenvironment of the tumour leads to exhaustion and death of effector cells. Rationally designed delivery technologies such as lipid nanoparticles, hydrogels, scaffolds and polymeric nanoparticles are uniquely suited to overcome these challenges through the targeted delivery of therapeutics to tumour cells, immune cells or the extracellular matrix. Here, we discuss delivery technologies that have the potential to reduce various clinical barriers for in situ cancer vaccines. We also provide our perspective on this emerging field that lies at the interface of cancer vaccine biology and delivery technologies.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: